Back to Report Store Home

Global Gastrointestinal Drug Market to 2022 – Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape

  • Published: Sep-2016
  • Report Code: GBIHC414MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Epidemiology Patterns for Gastroesophageal Reflux Disease (million), 2015–2022 18

Figure 2: Epidemiology Patterns for Irritable Bowel Syndrome (million), 2015–2022 19

Figure 3: Epidemiology Patterns for Inflammatory Bowel Disease (million), 2015–2022 19

Figure 4: Gastrointestinal Disorders, Global, Key Marketed Products and Approved Indications, 2016 25

Figure 5: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006–2022 26

Figure 6: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Remicade ($bn), 2006–2022 28

Figure 7: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Soliris ($bn), 2006–2022 29

Figure 8: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Tysabri ($bn), 2010–2022 31

Figure 9: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Nexium ($bn), 2006–2022 33

Figure 10: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Entyvio ($bn), 2014–2022 35

Figure 11: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Protonix ($bn), 2006–2022 36

Figure 12: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Ocaliva ($bn), 2016–2022 38

Figure 13: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Dexilant ($bn), 2008–2022 39

Figure 14: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Amitiza ($bn), 2006–2022 41

Figure 15: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Takecab ($bn), 2014–2022 43

Figure 16: Gastrointestinal Therapeutics Market, Global, Annual Revenue for Linzess ($bn), 2012–2022 44

Figure 17: Gastrointestinal Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 45

Figure 18: Gastrointestinal Therapeutics Market, Global, Gastrointestinal Pipeline by Stage of Development and Molecule Type, 2016 46

Figure 19: Gastrointestinal Therapeutics Market, Global, Pipeline for Key Gastrointestinal Indications by Stage of Development, 2016 47

Figure 20: Gastrointestinal Therapeutics Market, Global, Pipeline for Key Gastrointestinal Indications by Molecule Type, 2016 48

Figure 21: Gastrointestinal Therapeutics Market, Global, Gastrointestinal Pipeline by Molecular Target, 2016 49

Figure 22: Gastrointestinal Therapeutics Market, Global, Pipeline for Key Gastrointestinal Indications by Molecular Target, 2016 50

Figure 23: Gastrointestinal Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016 51

Figure 24: Gastrointestinal Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016 52

Figure 25: Gastrointestinal Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016 53

Figure 26: Gastrointestinal Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016 54

Figure 27: Gastrointestinal Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016 55

Figure 28: Gastrointestinal Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 56

Figure 29: Gastrointestinal Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 57

Figure 30: Gastrointestinal Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 58

Figure 31: Gastrointestinal Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2016 59

Figure 32: Gastrointestinal Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016 60

Figure 33: Gastrointestinal Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 61

Figure 34: Gastrointestinal Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 62

Figure 35: Gastrointestinal Therapeutics Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2016 63

Figure 36: Gastrointestinal Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 64

Figure 37: Gastrointestinal Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016 64

Figure 38: Gastrointestinal Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 65

Figure 39: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for RPC1063 ($m), 2018–2022 66

Figure 40: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for GED-0301 ($m), 2018–2022 67

Figure 41: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for Stelara ($m), 2018–2022 68

Figure 42: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for Victoza ($m), 2018–2022 70

Figure 43: Gastrointestinal Therapeutics Market, Global, Revenue Forecast for Plecanatide ($m), 2017–2022 71

Figure 44: Gastrointestinal Therapeutics Market, Global, Market Size ($bn), 2015–2022 73

Figure 45: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2015–2022 75

Figure 46: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Tumor Necrosis Factor Alpha Inhibitors ($bn), 2015–2022 77

Figure 47: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2018–2022 78

Figure 48: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for H+/K+ ATPase Inhibitors ($bn), 2015–2022 79

Figure 49: Gastrointestinal Therapeutics Market, Global, Annual Revenue Forecast for Integrin Inhibitors ($bn), 2015–2022 80

Figure 50: Gastrointestinal Therapeutics Market, Global, Cluster by Growth and Market Share, 2015–2022 81

Figure 51: Gastrointestinal Therapeutics Market, Global, Forecast Market Share by Company (%), 2015–2022 85

Figure 52: Gastrointestinal Therapeutics Market, Global, Companies by Compound Annual Growth Rate (%), 2015–2022 86

Figure 53: Gastrointestinal Therapeutics Market, Global, Revenues by Product Type, 2015–2022 87

Figure 54: Gastrointestinal Therapeutics Market, Global, AbbVie Annual Revenue Forecast ($bn), 2015–2022 88

Figure 55: Gastrointestinal Therapeutics Market, Global, Takeda Annual Revenue Forecast ($bn), 2015–2022 90

Figure 56: Gastrointestinal Therapeutics Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015–2022 91

Figure 57: Gastrointestinal Therapeutics Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2015–2022 93

Figure 58: Gastrointestinal Therapeutics Market, Global, Alexion Annual Revenue Forecast ($bn), 2015–2022 94

Figure 59: Gastrointestinal Therapeutics Market, Global, Allergan Annual Revenue Forecast ($bn), 2015–2022 96

Figure 60: Gastrointestinal Therapeutics Market, Global, Celgene Annual Revenue Forecast ($bn), 2015–2022 97

Figure 61: Gastrointestinal Therapeutics Market, Global, Companies by Type, 2016 98

Figure 62: Gastrointestinal Therapeutics Market, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Gastrointestinal Specialization, 2016 99

Figure 63: Gastrointestinal Therapeutics Market, Global, Proportion of Total Company Revenue Attributed to Gastrointestinal, 2015–2022 100

Figure 64: Gastrointestinal Therapeutics Market, Global, Licensing Deals by Region, Year and Value, 2006–2015 102

Figure 65: Gastrointestinal Therapeutics Market, Global, Licensing Deals by Indication, 2006–2016 103

Figure 66: Gastrointestinal Therapeutics Market, Global, Licensing Deals by Stage of Development and Value, 2006–2016 104

Figure 67: Gastrointestinal Therapeutics Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2016 105

Figure 68: Gastrointestinal Therapeutics Market, Global, Co-development Deals by Region, Year and Value, 2006–2016 107

Figure 69: Gastrointestinal Therapeutics Market, Global, Co-development Deals by Indication, 2006–2016 108

Figure 70: Gastrointestinal Therapeutics Market, Global, Co-development Deals by Stage of Development and Value, 2006–2016 109

Figure 71: Gastrointestinal Therapeutics Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2016 110

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards